BR112014025855A8 - Uso de um anticorpo anti-mif em combinação com um agente quimioterapêutico combinação, e, kit - Google Patents

Uso de um anticorpo anti-mif em combinação com um agente quimioterapêutico combinação, e, kit

Info

Publication number
BR112014025855A8
BR112014025855A8 BR112014025855A BR112014025855A BR112014025855A8 BR 112014025855 A8 BR112014025855 A8 BR 112014025855A8 BR 112014025855 A BR112014025855 A BR 112014025855A BR 112014025855 A BR112014025855 A BR 112014025855A BR 112014025855 A8 BR112014025855 A8 BR 112014025855A8
Authority
BR
Brazil
Prior art keywords
decoder
conference call
conference
combination
network server
Prior art date
Application number
BR112014025855A
Other languages
English (en)
Other versions
BR112014025855A2 (pt
Inventor
Kerschbaumer Randolf
Scheiflinger Friedrich
Ehrlich Hartmut
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48625989&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014025855(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of BR112014025855A2 publication Critical patent/BR112014025855A2/pt
Publication of BR112014025855A8 publication Critical patent/BR112014025855A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

MÉTODO PARA UM DECODIFICADOR IMPLANTAR UMA CHAMADA DE CONFERÊNCIA COM MÚLTIPLOS PARTICIPANTES, MÉTODO PARA UM SERVIDOR DE REDE PROCESSAR UMA CHAMADA DE CONFERÊNCIA COM MÚLTIPLOS PARTICIPANTES DE UM DECODIFICADOR, MÉTODO PARA UM DECODIFICADOR E UM SERVIDOR DE REDE COOPERAREM PARA IMPLANTAR UMA CHAMADA DE CONFERÊNCIA COM MÚLTIPLOS PARTICIPANTES, DECODIFICADOR PARA IMPLANTAR UMA CHAMADA DE CONFERÊNCIA COM MÚLTIPLOS PARTICIPANTES, SERVIDOR DE REDE PARA IMPLANTAR UMA CHAMADA DE CONFERÊNCIA COM MÚLTIPLOS PARTICIPANTES, E SISTEMA PARA IMPLANTAR UMA CHAMADA DE CONFERÊNCIA COM MÚLTIPLOS PARTICIPANTES Trata-se de um método, um dispositivo e um sistema para implantar uma chamada de conferência com múltiplos participantes com o uso de um decodificador. O método compreende: em um estado de conferência, o decodificador enviar uma mensagem de solicitação a um servidor de rede que gerencia a conferência para adicionar outro decodificador especificado à conferência em que o decodificador está localizado; e após o decodificador receber uma mensagem de confirmação retroalimentada pelo servidor de rede e indicar que o decodificador especificado foi adicionado à conferência, o decodificador distribuir sinais de áudio e/ou vídeo a serem transmitidos pelo decodificador para outros membros da conferência através do servidor de rede.
BR112014025855A 2012-04-16 2013-04-16 Uso de um anticorpo anti-mif em combinação com um agente quimioterapêutico combinação, e, kit BR112014025855A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261624964P 2012-04-16 2012-04-16
US201261668932P 2012-07-06 2012-07-06
US201361778094P 2013-03-12 2013-03-12
PCT/EP2013/057894 WO2013156473A1 (en) 2012-04-16 2013-04-16 Combination therapy of anti-mif antibodies and chemotherapeutics

Publications (2)

Publication Number Publication Date
BR112014025855A2 BR112014025855A2 (pt) 2017-06-20
BR112014025855A8 true BR112014025855A8 (pt) 2017-07-25

Family

ID=48625989

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014025855A BR112014025855A8 (pt) 2012-04-16 2013-04-16 Uso de um anticorpo anti-mif em combinação com um agente quimioterapêutico combinação, e, kit

Country Status (16)

Country Link
US (1) US20150071942A1 (pt)
EP (2) EP2838561A1 (pt)
JP (2) JP2015514735A (pt)
KR (2) KR20150027048A (pt)
CN (2) CN104812411A (pt)
AU (1) AU2013202693B2 (pt)
BR (1) BR112014025855A8 (pt)
CA (1) CA2869990A1 (pt)
CL (2) CL2014002788A1 (pt)
CO (1) CO7131377A2 (pt)
HK (1) HK1206985A1 (pt)
IL (2) IL235038A0 (pt)
MX (1) MX2014012535A (pt)
NZ (1) NZ628363A (pt)
RU (2) RU2014145887A (pt)
WO (1) WO2013156473A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11402388B2 (en) 2012-07-10 2022-08-02 Takeda Pharmaceutical Company Limited Anti-MIF immunohistochemistry
US10613100B2 (en) * 2014-01-03 2020-04-07 Baxalta Incorporated Anti-MIF immunohistochemistry
EP3277718B1 (en) 2015-03-31 2021-03-24 Baxalta GmbH Dosage regimen for anti-mif antibodies
US20180155419A1 (en) 2015-05-18 2018-06-07 Baxalta GmbH Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030615A (en) * 1993-05-17 2000-02-29 The Picower Institute For Medical Research Combination method for treating diseases caused by cytokine-mediated toxicity
US6774227B1 (en) * 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
JP4708510B2 (ja) * 1993-05-17 2011-06-22 サイトカイン ファーマサイエンシズ，インコーポレーテッド サイトカイン媒介毒性に関係する疾患の治療における遊走阻止因子の抑制
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
AU2004204778B2 (en) * 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
RU2389507C2 (ru) * 2004-07-02 2010-05-20 Ньютек Фарма Плс Лечение рака
CA2633486C (en) * 2005-12-16 2015-02-03 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
CN100457895C (zh) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
NZ586600A (en) * 2008-01-04 2012-05-25 Baxter Int Anti macrophage migration inhibitory factor antibodies
EP2525820B1 (en) * 2010-01-19 2016-05-11 Immunomedics, Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
JP2014530360A (ja) * 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ
EP2753937B1 (en) * 2011-10-07 2018-01-17 Baxalta GmbH Characterization of cho-mif gene and protein, and use thereof

Also Published As

Publication number Publication date
HK1206985A1 (en) 2016-01-22
RU2014145887A (ru) 2016-06-10
CL2016001327A1 (es) 2017-01-06
CO7131377A2 (es) 2014-12-01
NZ628363A (en) 2017-02-24
US20150071942A1 (en) 2015-03-12
KR20160049047A (ko) 2016-05-04
RU2016117260A3 (pt) 2018-10-23
CN106139143A (zh) 2016-11-23
RU2016117260A (ru) 2018-10-23
CN104812411A (zh) 2015-07-29
AU2013202693B2 (en) 2015-01-22
BR112014025855A2 (pt) 2017-06-20
JP2015514735A (ja) 2015-05-21
EP2838561A1 (en) 2015-02-25
IL245604A0 (en) 2016-06-30
IL235038A0 (en) 2014-12-31
WO2013156473A1 (en) 2013-10-24
CA2869990A1 (en) 2013-10-24
CL2014002788A1 (es) 2015-02-06
AU2013202693A1 (en) 2013-10-31
MX2014012535A (es) 2015-04-10
JP2016175918A (ja) 2016-10-06
EP3064221A1 (en) 2016-09-07
KR20150027048A (ko) 2015-03-11

Similar Documents

Publication Publication Date Title
BR112017004387A2 (pt) sistema e método para rastrear eventos e fornecer retroinformação em uma conferência virtual
BR112017021350A2 (pt) gerenciamento de áudio de conferência
MX2017016919A (es) Fusión de llamadas activas de grupo.
BR112014025855A8 (pt) Uso de um anticorpo anti-mif em combinação com um agente quimioterapêutico combinação, e, kit
WO2012177564A3 (en) Automatic sharing of event content by linking devices
MX2017006497A (es) Sistema colaborativo de expedicion de boletos.
EP3556128A4 (en) NETWORK ARCHITECTURE WITH MULTICAST AND BROADCAST MULTIMEDIA SUBSYSTEM CAPACITY
MX2017016208A (es) Sistema de presentacion de difusion multimedia en tiempo real.
MX2017016928A (es) Fusión de llamadas activas de grupo.
BR112015018366A2 (pt) sistema de compartilhamento de mídia que proporciona uma experiência compartilhada de conteúdo de mídia licenciado
WO2008005340A3 (en) Online conferencing systems for sharing documents
WO2014075087A3 (en) Systems and methods for communicating a live event to users using the internet
BR112018017292A2 (pt) informações de sincronização de difusões de dispositivo de origem associadas a um canal isócrono de bluetooth
BR112018009271A2 (pt) sistemas e métodos para processar conteúdo com uso de redes neurais convolucionais
ATE541381T1 (de) Steuerung der inhaltsablieferung in broadcast/multicast-netzwerken
MX2019014416A (es) Suministro de video en 360 grados a través de la red de próxima generación.
ES2531117T3 (es) Método, aparato y sistema para convergencia de conferencia de multiplataforma
BR112016009600A2 (pt) Continuidade de serviços para comunicações em grupo através de serviço de difusão multidifusão de multimídia evoluído
WO2009156867A3 (en) Systems,methods, and media for providing cascaded multi-point video conferencing units
GB2508123A (en) Stream processing using a client-server architecture
BR112017005127A2 (pt) elemento de rede de processamento de serviço de difusão/multidifusão de multimídia evoluído e método de difusão de serviço de difusão/multidifusão de multimídia evoluído
EP4280484A3 (en) Synchronized audio mixing
BR112013021667A2 (pt) operação distribuída de um sistema de posicionamento local
BR112013019302A2 (pt) sistema de interação de localização múltipla e método para proporcionar experiência interativa a dois ou mais participantes localizados em um ou mais nós interativos
WO2011097136A3 (en) Method and apparatus for providing call conferencing services

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B25B Requested transfer of rights rejected

Owner name: BAXTER HEALTHCARE S.A. (CH) , BAXTER INTERNATIONAL INC. (US)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 870160014476 DE 18/04/2015, CONFORME DISPOSTO NO ART. 59 DA LEI 9279 DE 14/05/1996, PELO FATO DO PEDIDO DE PATENTE TER SIDO ARQUIVADO DEFINITIVAMENTE NA RPI 2443 DE 31/10/2017.

Owner name: BAXTER HEALTHCARE S.A. (CH) , BAXTER INTERNATIONAL